Earnings Release • Mar 2, 2020
Earnings Release
Open in ViewerOpens in native device viewer


28 February 2020

a
Growth in GPW of 9.7%, growth in operating revenues of 10.1%
Net profit of €50.2 million and ROE of 13.8%, which includes a one-off positive effect on the reversal of badwill relating to the acquisition of Ergo of €7.5 m
Net combined ratio (excl. FX) of 93.8%, which is within the target range
v First consolidation of new companies:
Issue of 20-year subordinated bonds worth €75 m with first call date in 2029
Signed deals to acquire Bled Diagnostic Centre and NLB Vita
Unaudited data.

| 2018 | 2019 plan | 2019 actual* |
|
|---|---|---|---|
| Group | |||
| Operating revenues | €531.3 m | > €535 m | €584.9 m |
| Profit or loss, net of tax | €43.0 m | > €43 m |
€50.2 m |
| Return on equity | 13.1% | > 12% | 13.8% |
| v Investment return** |
1.7% | 1.7% | 1.9% |
| (Re)insurance part (+ annuities) | |||
| Gross premiums written | €546.3 m | > €555 m | €599.3 m |
| Net expense ratio** (reins. + non-life + life) |
33.1% | 32.4‒33.0% | 31.7% |
| Net combined ratio** (reins. + non-life) | 92.9% | 93.6‒94.1% | 93.8% |
* Unaudited data.
4
** Excluding the effect of exchange differences. The investment return does not include the expenses of subordinated debt.





Global markets Sava Re reinsurance business Non-Group premiums: €90.3 m 2019/18: +1.0%
Unaudited data.

Thank you for your attention.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.